Coloplast Future Growth

Future criteria checks 3/6

Coloplast is forecast to grow earnings and revenue by 11% and 7.7% per annum respectively while EPS is expected to grow by 11.2% per annum.

Key information

11.0%

Earnings growth rate

11.2%

EPS growth rate

Medical Equipment earnings growth	0%
Revenue growth rate	7.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	18 May 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BMV:0QBO N - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2025	28,820	6,541	6,167	7,542	14
9/30/2024	26,707	5,885	5,587	6,879	17
9/30/2023	24,748	5,107	4,809	6,220	18
3/31/2023	24,074	4,801	3,663	4,894	N/A
12/31/2022	23,515	4,626	3,246	4,455	N/A
9/30/2022	22,579	4,706	3,964	5,099	N/A
6/30/2022	21,620	4,781	3,894	4,913	N/A
3/31/2022	20,606	4,746	3,735	4,712	N/A
12/31/2021	19,857	4,896	4,272	5,209	N/A
9/30/2021	19,426	4,825	3,324	5,290	N/A
6/30/2021	18,916	4,561	3,102	5,023	N/A
3/31/2021	18,500	4,304	3,162	5,077	N/A
12/31/2020	18,570	4,241	3,003	4,941	N/A
9/30/2020	18,544	4,197	3,828	4,759	N/A
6/30/2020	18,572	3,949	3,876	4,842	N/A
3/31/2020	18,752	4,020	3,872	4,764	N/A
12/31/2019	18,330	3,974	3,833	4,615	N/A
9/30/2019	17,939	3,873	3,667	4,357	N/A
6/30/2019	17,555	4,119	3,599	4,161	N/A
3/31/2019	17,181	3,999	3,562	4,177	N/A
12/31/2018	16,815	3,896	3,522	4,126	N/A
9/30/2018	16,449	3,845	3,692	4,361	N/A
6/30/2018	16,195	3,816	3,587	4,370	N/A
3/31/2018	15,882	3,778	3,361	4,111	N/A
12/31/2017	15,728	3,791	3,235	4,004	N/A
9/30/2017	15,528	3,797	2,566	3,251	N/A
6/30/2017	15,287	3,211	2,308	2,994	N/A
3/31/2017	15,061	3,279	1,808	2,492	N/A
12/31/2016	14,780	3,264	N/A	2,653	N/A
9/30/2016	14,681	3,143	N/A	3,028	N/A
6/30/2016	14,563	1,297	N/A	3,081	N/A
3/31/2016	14,417	1,028	N/A	3,568	N/A
12/31/2015	14,264	927	N/A	3,320	N/A
9/30/2015	13,909	899	N/A	3,337	N/A
6/30/2015	13,502	3,162	N/A	3,119	N/A
3/31/2015	13,096	3,241	N/A	3,015	N/A
12/31/2014	12,666	2,407	N/A	3,193	N/A
9/30/2014	12,428	2,390	N/A	3,149	N/A
6/30/2014	12,184	2,298	N/A	3,177	N/A
3/31/2014	12,008	2,220	N/A	3,074	N/A
12/31/2013	11,833	2,874	N/A	3,270	N/A
9/30/2013	11,635	2,711	N/A	3,136	N/A
6/30/2013	11,514	2,570	N/A	2,912	N/A
3/31/2013	11,384	2,448	N/A	2,907	N/A
12/31/2012	11,234	2,327	N/A	2,894	N/A
9/30/2012	11,023	2,194	N/A	2,649	N/A
6/30/2012	10,745	2,117	N/A	2,686	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0QBO N's forecast earnings growth (11% per year) is above the savings rate (7.6%).

Earnings vs Market: 0QBO N's earnings (11% per year) are forecast to grow faster than the MX market (9.2% per year).

High Growth Earnings: 0QBO N's earnings are forecast to grow, but not significantly.

Revenue vs Market: 0QBO N's revenue (7.7% per year) is forecast to grow faster than the MX market (6.2% per year).

High Growth Revenue: 0QBO N's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 0QBO N's Return on Equity is forecast to be high in 3 years time

Coloplast Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies